We are an immediate loan specialist in Washington, and we are quicker and more advantageous than run of the mill retail facade banks since we're based on the web and are open constantly. No compelling reason to sit tight for "ordinary business hours" or invest energy flying out to the store — our short application can be finished in not more than minutes. You can even apply from a cell phone while you're in a hurry!
We can loan up to $500 to Washington occupants, in view of qualifying elements. On the off chance that endorsed, your credit will be expected on your next payday that falls in the vicinity of 10 and 31 days after you get your advance. As you consider whether an advance is proper for your prompt needs, you ought to likewise investigate other subsidizing alternatives. A payday credit is a genuine budgetary duty, and not an answer for long haul issues. Getting from a companion of relative may be a superior alternative.
I'm really worried that I'll fall into the penny stock trap. But this stock has good liquidity and cnn, msn, yahoo fianance are all giving this stock a "buy" and I've noticed the same thing for other penny stocks as well? Are their valuations wrong? What's the catch? If I buy 1500 shares is that a bad idea? Thanks a lot
Penny Stock is not an exact definition. Stocks under $5 a share are generally only purchased in specialty mutual funds. Aurinia Pharmaceuticals Inc AUPH Closed at @2.53 Volume of a million shares in a day is normal Biotech sector has generally been down resulting from statements from Clinton and Trump, and an expected dismantling of Obamacare in 2017. Schwab, Morningstar Equity, Credit Suisse, Ned Davis, Argus - all show NO RATINGS S&P Capital IQ's Opinion - STRONG SELL. S+P Capital opinion is based on a quantitative model Quantitative using Valuation, Quality, Growth, Financial Health, Street Sentiment, Price Momentum There are 4 analysts covering the stock with recommendations. My basic review as a seasoned INVESTOR (not short term trader) who tends to be on the conservative side, but willing to take a risk on small amounts of a stock where risk-return ratios look good: This Toronto Canada pharmaceutical clinical level research firm with 15 employees is running on equity financing with no appreciable income and bleeds money. Most recent key news is an end of year equity financing for US$28.75 million financing via the sale of 12,777,775 units at US$2.25 per Unit. Each Unit consists of one common share and one-half of one common share purchase warrant at the exercise price of US$3.00 per Share for a period of 5 years. That sale there values shares at about $2 each or so. It has a dilutive effect on future earnings. Company on Sept 30, 2016 had US$17 million in cash and non-fixed tangible assets, $26 thousand in property and equipment, $13.1 million in liabilities and commitments, intangible assets shown as $15.9 million. Adding subsequent financing and pending other expenses for the 4th quarter, $45 million in real assets minus $13 million liability puts book value at $32 million, and common shares at 51.8 million and warrants plus diluting warrants and options so about $0.62 per share in tangible value minus last quarter expenses. They have minimal revenue and have reduced expenses to $6.5 million in the third quarter. They have what appears to be operating expenses for a year or two and should continue to issue shares for financing. I live in Las Vegas. Yesterday I was watching a roulette wheel for the last 25 numbers hit and #8 hit 5 times and #10 4 times and they are in one section of the wheel with 3 other hits in the same physical quarter section of the 38 number reel. I did not stop to play but saw what could be a slanted wheel putting a favorable 9 number bet, if it continued, into an extremely large return. This was a far better opportunity than a company bleeding its money and diluting the owner's equity. The drugs of the company seem to be getting positive reports some in stage 2 trials, but no real outlook for a couple of years at least to actually earn money on product. If its products are successful, you can make a lot of money and if there is any glitches in the path, this company can close its doors. If you have some reason to see more than the public available information, or if you bet on short term trading curves showing a 2017 rise pattern, you can take a gamble with your money and see what happens. Now, about your comments - This company has BAD liquidity as it is operating on a pattern of share dilution rather than profit. The CNN, MSN, Yahoo Finance, and other positive reports are the same 4 analysts who probably are invested in shares. "You wanna take a gamble?" Feel free to invest money you can afford to lose if you have a hunch. There are no indications of success, but traders push prices up and down. Yesterday's roulette wheel looked far better, but I did not want to hang around at the time. Penny stocks get hyped up. "Are their valuations wrong?" They are not VALUATIONS or EVALUATIONS either. They are looking at four people who like the shares potentials, and I see S+P analyst formula saying it is dead meat on paper. There is nothing wrong with having risk capital to play with, but whether this one is the right one, I would need convincing. There are thousands of companies like it. The only bad idea is buying shares with money you cannot afford to lose, especially in risky plays. IMPORTANT NOTE: I OWN NO SHARES OF AUPH unless in mutual funds I happen to have shares of. I MAKE NO RECOMMENDATION TO BUY washington SELL ANYTHING. I am presenting an opinion and my short research. Do your own due diligence. Anyone telling you either to buy or sell is spouting a random thought most likely. The analysts are not in a position to evaluate this company really. If I were going to buy any, I prefer the $2 price the December investors got instead of the $2.53, but the market price is $2.53 which is its current value per share. Market cap $133 Million. About $33 million in actual paper value today, so $100 million in intangible "wishes" value. Feel free to make a wish and buy shares.